Although some preliminary reports suggest that NAC may be beneficial in treating these conditions, many of the studies involved small groups of patients who took variable doses of NAC, and because of this, the study results are not generalizable to the population as a whole
Also, the Trump administration is stepping back from the indirect cost fight at the NIH, and new data suggest genetics may modestly influence responses to GLP-1 drugs
Leave a comment below on the weight loss drug movement that's been happening very recently, and let me know what you think
[1] Baseline Cardiovascular Profile The SELECT study is a large cardiovascular outcomes trial designed to assess whether semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), can reduce cardiovascular events in people who are overweight or obese but do not have diabetes
18: Windram M, Lovelock DF, Carew JM, Krieman CG, Hendershot CS, Besheer J
While there is no definitive evidence to suggest that semaglutide directly affects the menstrual cycle, individual experiences vary, and weight loss associated with the medication may have indirect effects